MVCD7
MCID: MCR120
MIFTS: 47

Microvascular Complications of Diabetes 7 (MVCD7)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Microvascular Complications of Diabetes 7

MalaCards integrated aliases for Microvascular Complications of Diabetes 7:

Name: Microvascular Complications of Diabetes 7 57 73 12
Microvascular Complications of Diabetes, Susceptibility to, 7 57 28 5
Diabetic Nephropathy 73 71
Mvcd7 57 73
Nonproliferative Retinopathy, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
Microvascular Complications of Diabetes, Type 7 38
Nephropathy, Diabetic, Susceptibility to 57
Nonproliferative Retinopathy, Diabetic 57
Diabetic Non-Proliferative Retinopathy 73
Proliferative Retinopathy, Diabetic 57
Proliferative Diabetic Retinopathy 71
Diabetic Proliferative Retinopathy 73
Nephropathy, Diabetic 57

Classifications:



External Ids:

OMIM® 57 612635
OMIM Phenotypic Series 57 PS603933
MeSH 43 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 7

UniProtKB/Swiss-Prot: 73 Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 7, also known as microvascular complications of diabetes, susceptibility to, 7, is related to hemochromatosis, type 1 and transferrin serum level quantitative trait locus 2. An important gene associated with Microvascular Complications of Diabetes 7 is HFE (Homeostatic Iron Regulator). The drugs Pentoxifylline and Captopril have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612635 PS603933

Related Diseases for Microvascular Complications of Diabetes 7

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 7 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 558)
# Related Disease Score Top Affiliating Genes
1 hemochromatosis, type 1 29.5 HFE-AS1 HFE
2 transferrin serum level quantitative trait locus 2 29.3 HFE-AS1 HFE
3 cystic fibrosis 29.3 HFE-AS1 HFE
4 porphyria cutanea tarda 29.3 HFE-AS1 HFE
5 variegate porphyria 29.2 HFE-AS1 HFE
6 alzheimer disease, familial, 1 28.9 HFE-AS1 HFE
7 microvascular complications of diabetes 1 11.5
8 microvascular complications of diabetes 2 11.5
9 type 1 diabetes mellitus 11.5
10 microvascular complications of diabetes 3 11.3
11 microvascular complications of diabetes 4 11.3
12 microvascular complications of diabetes 6 11.3
13 diabetic angiopathy 11.2
14 maturity-onset diabetes of the young 11.2
15 hyperglycemia 11.1
16 type 2 diabetes mellitus 11.1
17 renal fibrosis 11.1
18 oto-palatal-digital syndrome 11.0
19 diabetes mellitus 11.0
20 chronic kidney disease 11.0
21 glomerulonephritis 10.8
22 lipid metabolism disorder 10.8
23 nephrotic syndrome 10.7
24 hypertension, essential 10.7
25 rickets 10.7
26 vascular disease 10.7
27 ceroid lipofuscinosis, neuronal, 5 10.6
28 uremia 10.6
29 iga glomerulonephritis 10.6
30 iga nephropathy 1 10.6
31 membranous nephropathy 10.6
32 down syndrome 10.5
33 mckusick-kaufman syndrome 10.5
34 abdominal obesity-metabolic syndrome 1 10.5
35 hypercholesterolemia, familial, 1 10.5
36 cardiovascular system disease 10.5
37 neuropathy 10.5
38 kidney hypertrophy 10.5
39 peripheral vascular disease 10.5
40 glomerular disease 10.5
41 arteriosclerosis 10.5
42 lipoid nephrosis 10.5
43 leptin deficiency or dysfunction 10.5
44 focal segmental glomerulosclerosis 10.5
45 glucose intolerance 10.5
46 hypolipoproteinemia 10.5
47 deficiency anemia 10.5
48 pre-eclampsia 10.5
49 autonomic neuropathy 10.5
50 familial hyperlipidemia 10.5

Comorbidity relations with Microvascular Complications of Diabetes 7 via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Chronic Kidney Disease
Deficiency Anemia Diabetic Cataract
Diabetic Polyneuropathy Heart Disease
Hypertension, Essential Hypoglycemia
Microvascular Complications of Diabetes 1 Peripheral Vascular Disease
Rubeosis Iridis

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 7:



Diseases related to Microvascular Complications of Diabetes 7

Symptoms & Phenotypes for Microvascular Complications of Diabetes 7

Clinical features from OMIM®:

612635 (Updated 08-Dec-2022)

Drugs & Therapeutics for Microvascular Complications of Diabetes 7

Drugs for Microvascular Complications of Diabetes 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 347)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
2
Captopril Approved Phase 4 62571-86-2 44093
3
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
4
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
5
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
6
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
7
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
8
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
9
Mecobalamin Approved, Investigational Phase 4 13422-55-4
10
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
11
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Atenolol Approved Phase 4 29122-68-7 2249
14
Doxazosin Approved Phase 4 74191-85-8 3157
15
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
16
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
17
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
18
Simvastatin Approved Phase 4 79902-63-9 54454
19
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
20
Insulin glulisine Approved Phase 4 207748-29-6
21
Insulin glargine Approved Phase 4 160337-95-1 118984454
22
Lixisenatide Approved Phase 4 320367-13-3 90472060 16139342
23
Glucagon Approved Phase 4 16941-32-5 16133228 16186314
24
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
25
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
26
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
27
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
28
Carbamide peroxide Approved Phase 4 124-43-6
29
Candesartan cilexetil Approved Phase 4 145040-37-5
30
Allopurinol Approved Phase 4 315-30-0 2094 135401907
31
Nisoldipine Approved Phase 4 63675-72-9 4499
32
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
33
Probucol Approved, Investigational Phase 4 23288-49-5 4912
34
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
35
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
36
Atorvastatin Approved Phase 4 134523-00-5 60823
37
Indapamide Approved Phase 4 26807-65-8 3702
38
Insulin lispro Approved Phase 4 133107-64-9 16132438
39
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
40
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
41
Trandolapril Approved Phase 4 87679-37-6 5484727
42
Saxagliptin Approved Phase 4 361442-04-8 11243969
43
Dipivefrin Approved Phase 4 52365-63-6 3105
44
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
45
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
46
Ertugliflozin Approved, Investigational Phase 4 1210344-57-2 75075340 44814423
47
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
48
Ranibizumab Approved Phase 4 347396-82-1
49 Grape Approved Phase 4
50
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020

Interventional clinical trials:

(show top 50) (show all 462)
# Name Status NCT ID Phase Drugs
1 Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study Unknown status NCT04127084 Phase 4 SGLT2 Inhibition
2 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
3 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
4 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
5 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
6 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
7 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
8 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
9 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Unknown status NCT03664414 Phase 4 pentoxifylline
10 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
11 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
12 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
14 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
15 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Unknown status NCT04464694 Phase 4 Ranibizumab
16 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
17 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
18 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Unknown status NCT04283162 Phase 4 Calcium Dobesilate
19 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
20 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
21 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
22 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
23 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
24 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
25 A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus Completed NCT02276196 Phase 4 Lixisenatide;Insulin glulisine
26 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
27 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
28 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Completed NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
29 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
30 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil 32mg
31 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
32 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
33 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
34 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
35 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
36 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
37 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
38 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
39 Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen. Completed NCT00296296 Phase 4 Cyclosporin;Tacrolimus
40 Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea Completed NCT02816762 Phase 4 Pharmacological treatment
41 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH
42 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
43 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
44 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
45 Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes Completed NCT02914691 Phase 4 Dapagliflozine 10 mg once daily tablet treatment;Placebo identical once daily tablet treatment
46 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
47 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
48 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
49 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
50 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil

Search NIH Clinical Center for Microvascular Complications of Diabetes 7

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 7

Genetic tests related to Microvascular Complications of Diabetes 7:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes, Susceptibility to, 7 28 HFE

Anatomical Context for Microvascular Complications of Diabetes 7

Organs/tissues related to Microvascular Complications of Diabetes 7:

MalaCards : Kidney, Endothelial, Pancreas, Retina, Eye, Bone Marrow, Heart

Publications for Microvascular Complications of Diabetes 7

Articles related to Microvascular Complications of Diabetes 7:

(show top 50) (show all 21059)
# Title Authors PMID Year
1
The HFE gene is associated to an earlier age of onset and to the presence of diabetic nephropathy in diabetes mellitus type 2. 62 57 5
15347835 2004
2
Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. 62 57 5
11423500 2001
3
Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. 57 5
18566337 2008
4
A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes. 57 5
14618419 2003
5
Proliferative retinopathy in a patient with diabetes mellitus and idiopathic haemochromatosis. 57 5
678784 1978
6
Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. 5
19084217 2009
7
Iron-overload-related disease in HFE hereditary hemochromatosis. 5
18504828 2008
8
Iron-overload-related disease in HFE hereditary hemochromatosis. 5
18499578 2008
9
Frequency of the hemochromatosis gene mutations in the population of Serbia and Montenegro. 5
16879202 2006
10
Association of porphyria cutanea tarda with hereditary hemochromatosis. 5
15280838 2004
11
Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. 5
15060098 2004
12
Hemochromatosis mutations in the general population: iron overload progression rate. 5
15070663 2004
13
The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. 5
14729817 2004
14
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. 5
14673107 2003
15
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. 5
12915468 2003
16
Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. 5
12436244 2002
17
The hemochromatosis protein HFE inhibits iron export from macrophages. 5
12429850 2002
18
Clinical haemochromatosis in HFE mutation carriers. 5
12241803 2002
19
Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? 5
11904676 2002
20
Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. 5
11812557 2002
21
Identification of an endogenous RNA transcribed from the antisense strand of the HFE gene. 5
11532995 2001
22
Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? 5
11358905 2001
23
Polymorphism in intron 4 of HFE may cause overestimation of C282Y homozygote prevalence in haemochromatosis. 5
10431233 1999
24
Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. 5
10401000 1999
25
The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. 5
10381492 1999
26
Celtic origin of the C282Y mutation of hemochromatosis. 5
9851897 1998
27
Hemochromatosis in Ireland and HFE. 5
9851896 1998
28
The hemochromatosis 845 G-->A and 187 C-->G mutations: prevalence in non-Caucasian populations. 5
9585606 1998
29
Targeted disruption of the HFE gene. 5
9482831 1998
30
Phenotype-genotype correlation in haemochromatosis subjects. 5
9439654 1997
31
Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. 5
9356458 1997
32
A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. 5
9341868 1997
33
The significance of the 187G (H63D) mutation in hemochromatosis. 5
9326341 1997
34
Homozygosity for the predominant Cys282Tyr mutation and absence of disease expression in hereditary haemochromatosis. 5
9321765 1997
35
The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. 5
9162021 1997
36
Global prevalence of putative haemochromatosis mutations. 5
9138148 1997
37
Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. 5
9106528 1997
38
Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. 5
9024376 1997
39
Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (Mzab), Ethiopia, and Senegal. 5
9211748 1997
40
Haemochromatosis and HLA-H. 5
8896550 1996
41
Haemochromatosis and HLA-H. 5
8896549 1996
42
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. 5
8696333 1996
43
Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. 62
36375645 2023
44
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy. 62
36280016 2023
45
Beneficial effects of ginsenosides on diabetic nephropathy: A systematical review and meta-analysis of preclinical evidence. 62
36341813 2023
46
Suppression of lncRNA Snhg1 inhibits high glucose-induced inflammation and proliferation in mouse mesangial cells. 62
36243327 2023
47
The changing trajectory of diabetic kidney disease. 62
36250469 2023
48
Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. 62
36270460 2023
49
Ion channels and channelopathies in glomeruli. 62
36007181 2023
50
Modern indications for referral for kidney and pancreas transplantation. 62
36444661 2023

Variations for Microvascular Complications of Diabetes 7

ClinVar genetic disease variations for Microvascular Complications of Diabetes 7:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HFE-AS1, HFE NM_000410.4(HFE):c.187C>G (p.His63Asp) SNV Pathogenic
Risk Factor
10 rs1799945 GRCh37: 6:26091179-26091179
GRCh38: 6:26090951-26090951
2 HFE NM_000410.4(HFE):c.845G>A (p.Cys282Tyr) SNV Risk Factor
9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
3 HFE-AS1, HFE NM_000410.4(HFE):c.193A>T (p.Ser65Cys) SNV Uncertain Significance
11 rs1800730 GRCh37: 6:26091185-26091185
GRCh38: 6:26090957-26090957

Expression for Microvascular Complications of Diabetes 7

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 7.

Pathways for Microvascular Complications of Diabetes 7

GO Terms for Microvascular Complications of Diabetes 7

Sources for Microvascular Complications of Diabetes 7

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....